Found: 84
Select item for more details and to access through your institution.
A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder.
- Published in:
- Depression & Anxiety (1091-4269), 2009, v. 26, n. 1, p. 83, doi. 10.1002/da.20505
- By:
- Publication type:
- Article
Pricing medicines: theory and practice, challenges and opportunities.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 11, p. 1, doi. 10.1093/ofid/ofad513
- By:
- Publication type:
- Article
2510. Systematic Literature Review of Multiclass Resistance in Heavily Treatment Experienced Persons with HIV.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S871, doi. 10.1093/ofid/ofz360.2188
- By:
- Publication type:
- Article
Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.
- Published in:
- Infectious Diseases & Therapy, 2017, v. 6, n. 4, p. 477, doi. 10.1007/s40121-017-0167-9
- By:
- Publication type:
- Article
Estimating the Costs and Benefits of New Drug Therapies: Atypical Antipsychotic Drugs for Schizophrenia.
- Published in:
- Schizophrenia Bulletin, 2002, v. 28, n. 4, p. 619, doi. 10.1093/oxfordjournals.schbul.a006969
- By:
- Publication type:
- Article
Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.
- Published in:
- Applied Health Economics & Health Policy, 2022, v. 20, n. 2, p. 213, doi. 10.1007/s40258-021-00704-x
- By:
- Publication type:
- Article
Budget Impact Analysis of Cancer Screening: A Methodological Review.
- Published in:
- Applied Health Economics & Health Policy, 2019, v. 17, n. 4, p. 493, doi. 10.1007/s40258-019-00475-6
- By:
- Publication type:
- Article
Persistent challenges in Alzheimer's disease modeling: Pragmatic solutions to inform the road forward: Health services research / Cost‐effectiveness of treatment/prevention and diagnosis.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041141
- By:
- Publication type:
- Article
P2‐577: THE VARIABILITY IN INPUT PARAMETER VALUES IN MODELS ESTIMATING THE EFFECTIVENESS OF HYPOTHETICAL DISEASE MODIFYING TREATMENTS FOR ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P844, doi. 10.1016/j.jalz.2019.06.2986
- By:
- Publication type:
- Article
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United States.
- Published in:
- Vaccines, 2024, v. 12, n. 1, p. 74, doi. 10.3390/vaccines12010074
- By:
- Publication type:
- Article
The Impact of Social Determinants of Health on Meningococcal Vaccination Awareness, Delivery, and Coverage in Adolescents and Young Adults in the United States: A Systematic Review.
- Published in:
- Vaccines, 2023, v. 11, n. 2, p. 256, doi. 10.3390/vaccines11020256
- By:
- Publication type:
- Article
Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
- Published in:
- American Journal of Health-System Pharmacy, 2007, v. 64, n. 24, p. 2561, doi. 10.2146/ajhp060584
- By:
- Publication type:
- Article
Estimating the Bayesian loss function. A conjoint analysis approach.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of Their Diagnosis: A Patient Survey.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0086070
- By:
- Publication type:
- Article
Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
- Published in:
- American Journal of Health-System Pharmacy, 2013, v. 70, n. 17, p. 1518, doi. 10.2146/ajhp120599
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- European Journal of Health Economics, 2022, v. 23, n. 8, p. 1309, doi. 10.1007/s10198-021-01426-6
- By:
- Publication type:
- Article
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges.
- Published in:
- 2018
- By:
- Publication type:
- Editorial
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
- Published in:
- European Journal of Health Economics, 2013, v. 14, n. 3, p. 367, doi. 10.1007/s10198-013-0471-6
- By:
- Publication type:
- Article
Cost-effectiveness of treatment with etanercept for psoriasis in Sweden.
- Published in:
- European Journal of Health Economics, 2012, v. 13, n. 2, p. 145, doi. 10.1007/s10198-010-0293-8
- By:
- Publication type:
- Article
Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- International Journal of Technology Assessment in Health Care, 2022, v. 38, n. 1, p. 1, doi. 10.1017/S0266462321001732
- By:
- Publication type:
- Article
Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- International Journal of Technology Assessment in Health Care, 2021, v. 38, n. 1, p. 1, doi. 10.1017/S0266462321001732
- By:
- Publication type:
- Article
CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT.
- Published in:
- International Journal of Technology Assessment in Health Care, 2013, v. 29, n. 2, p. 117, doi. 10.1017/S0266462313000160
- By:
- Publication type:
- Article
RELATIONSHIP BETWEEN FINANCIAL IMPACT AND COVERAGE OF DRUGS IN AUSTRALIA.
- Published in:
- International Journal of Technology Assessment in Health Care, 2013, v. 29, n. 1, p. 92, doi. 10.1017/S0266462312000724
- By:
- Publication type:
- Article
Differences among formulary submission guidelines: Implications for health technology assessment.
- Published in:
- International Journal of Technology Assessment in Health Care, 2011, v. 27, n. 3, p. 261, doi. 10.1017/S0266462311000274
- By:
- Publication type:
- Article
Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs.
- Published in:
- World Journal of Surgical Oncology, 2012, v. 10, n. 1, p. 136, doi. 10.1186/1477-7819-10-136
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- MDM Policy & Practice, 2022, v. 7, n. 1, p. 1, doi. 10.1177/23814683211061097
- By:
- Publication type:
- Article
Patterns of ambulatory care for AIDS patients, and association with emergency room use.
- Published in:
- Health Services Research, 1994, v. 29, n. 4, p. 489
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- BMC Public Health, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12889-021-12491-0
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.
- Published in:
- Health Economics, 2008, v. 17, n. 3, p. 435, doi. 10.1002/hec.1274
- By:
- Publication type:
- Article
Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?
- Published in:
- Health Economics, 2003, v. 12, n. 7, p. 517, doi. 10.1002/hec.750
- By:
- Publication type:
- Article
A Methodological Review of US Budget-Impact Models for New Drugs.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 5, p. 535, doi. 10.1007/s40273-015-0277-8
- By:
- Publication type:
- Article
Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 9, p. 903, doi. 10.1007/s40273-014-0173-7
- By:
- Publication type:
- Article
Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 6, p. 521, doi. 10.1007/s40273-014-0157-7
- By:
- Publication type:
- Article
Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 4, p. 395, doi. 10.1007/s40273-014-0130-5
- By:
- Publication type:
- Article
A Methodological Review of Models Used to Estimate the Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV Infection.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 11, p. 1031, doi. 10.1007/s40273-013-0098-6
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 361, doi. 10.1007/s40273-013-0032-y
- By:
- Publication type:
- Article
Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
- Published in:
- 2011
- By:
- Publication type:
- journal article
US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 183, doi. 10.2165/11587520-000000000-00000
- By:
- Publication type:
- Article
US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 129, doi. 10.2165/11587490-000000000-00000
- By:
- Publication type:
- Article
Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 83, doi. 10.2165/11587470-000000000-00000
- By:
- Publication type:
- Article
A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection.
- Published in:
- PharmacoEconomics, 2010, v. 28, p. 1, doi. 10.2165/11587410-000000000-00000
- By:
- Publication type:
- Article